Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.64), $0.38 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $49.86 million versus the consensus estimate of $32.26 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.